These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159 [TBL] [Abstract][Full Text] [Related]
4. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma. Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401 [TBL] [Abstract][Full Text] [Related]
5. Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer. Mercier C; Claessens M; De Troyer B; Debacker T; Fransis K; Vandeursen H; Ost P; Dirix P Front Oncol; 2022; 12():863609. PubMed ID: 35494057 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: A phase II study. Choi SH; Lee BM; Kim J; Kim DY; Seong J J Hepatol; 2024 Jul; 81(1):84-92. PubMed ID: 38467379 [TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031 [TBL] [Abstract][Full Text] [Related]
8. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. Ali M; Mooi J; Lawrentschuk N; McKay RR; Hannan R; Lo SS; Hall WA; Siva S Eur Urol; 2022 Dec; 82(6):613-622. PubMed ID: 35843777 [TBL] [Abstract][Full Text] [Related]
9. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience. Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431 [TBL] [Abstract][Full Text] [Related]
10. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737 [TBL] [Abstract][Full Text] [Related]
11. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients. Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896 [TBL] [Abstract][Full Text] [Related]
12. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach. Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057 [TBL] [Abstract][Full Text] [Related]
13. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627 [TBL] [Abstract][Full Text] [Related]